NWPF

News ArchivesRead News

Medication Alone Insufficient in Treating Depression in Parkinson's Disease

Tuesday June 25, 2013

National Parkinson Foundation

Sacramento Bee - New findings from the National Parkinson Foundation (NPF) Parkinson's Outcomes Project show that antidepressants alone do not improve depression in Parkinson's disease. Depression was most effectively treated at centers that refer their depressed patients to a mental health professional or social worker. These findings were presented last week during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013.

In the study, "Approach to Treatment of Depression in Parkinson's Disease," Peter Schmidt, Ph.D., and colleagues examined which approaches to depression care correlated with the lowest prevalence of depression among patients seen at NPF's Centers of Excellence. Patients were treated with antidepressant medications, counseling by a social worker, treatment by a mental health professional, or a combination.

"This work is part of the larger NPF mission: to determine what works best in the treatment and care of Parkinson's with an aim toward slowing the impact of the disease," said Peter Schmidt, Ph.D., lead author of the study and Vice President, Programs at NPF. "This particular study highlights the importance of team care, something NPF has long advocated at its Centers of Excellence. We found the best care is achieved when neurologists coordinate with other health professionals to aggressively fight Parkinson's. In fact, a 'depression team,' consisting of a social worker and a psychiatrist coordinating with the neurologist, yielded the best results."

The study, analyzing 2,423 patients at 10 NPF Centers of Excellence found 1,121 depressed patients (46%), but at the best center only 30% showed signs of depression. Centers prescribed antidepressant medications to between 29% and 63% of their depressed patients, but high-prescribing centers achieved no significant reduction in depression versus low-prescribing centers. Other treatments, however, did correlate with better outcomes.

This work is part of the Parkinson's Outcomes Project, a longitudinal look at which treatments produce the best health outcomes. Started in 2009, the study represents data from more than 6,000 people with Parkinson's disease in four countries.

Recent News

May 2 - What's Good For The Heart Is Good For The Brain
Apr 29 - Press Release: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Apr 28 - Dopamine-making neurons can be chemically controlled in animal model of Parkinson's
Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions
Apr 9 - Commonly prescribed Parkinson's drugs up risk of compulsive gambling, shopping, binge eating, hypersexuality
Apr 7 - Pfizer and IBM Launch Innovative Research Project to Transform Parkinson's Disease Care
Apr 7 - Parkinson's Drug Highly Effective for Resistant Depression
Apr 5 - Speech therapy program helps Parkinson’s patients regain speaking ability
Apr 4 - New research maps out pesticide exposure and Parkinson's disease in Nebraska
Apr 4 - The rogue immune cells that wreck the brain
Mar 28 - Chemists identify structure of protein that forms fibrils in Parkinson's patients
Mar 25 - UPDATE 1-FDA staff says Acadia's drug for Parkinson's disease psychosis is effective
Mar 23 - The virus that could cure Alzheimer's, Parkinson's and more
Mar 21 - Antipsychotic drugs may do significantly more harm to Parkinson's disease patients
Mar 21 - Rosacea Might Boost Parkinson's Risk: Study
Mar 21 - Apple CareKit Could Completely Change What It's Like To Live With Parkinson's Disease & Epilepsy